NBRV Nabriva Therapeutics plc

8.47
+0.12  (1%)
Previous Close 8.35
Open 8.28
Price To book -1.08
Market Cap 253576351
Shares 29,938,176
Volume 1,478,111
Short Ratio 1.53
Av. Daily Volume 736,900

SEC filingsSee all SEC filings

  1. 8-K - Current report 171094271
  2. 424B5 - Prospectus [Rule 424(b)(5)] 171094207
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171091011
  4. 8-K - Current report 171089016
  5. 8-K - Current report 171088061

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due spring 2018.
Lefamulin - LEAP 2
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
Phase 3 data released September 18, 2017 - primary endpoint met.
Lefamulin - LEAP 1
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)

Latest News

  1. Nabriva Therapeutics’ latest good news soothes concerns about chief medical officer’s departure
  2. Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
  3. Why Nabriva Therapeutics Shares Are Falling Today
  4. Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
  5. Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP
  6. Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million
  7. Here's Why Nabriva Therapeutics PLC Is Soaring Today
  8. Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges
  9. Company News For Sep 19, 2017
  10. Today's Research Reports on Stocks to Watch: Itus Corporation and Nabriva Therapeutics
  11. Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares
  12. Here's Why Nabriva Therapeutics (NBRV) Stock is Surging Today
  13. Why Nabriva Therapeutics PLC Is Skyrocketing
  14. Northrop Grumman to buy Orbital ATK, Rite Aid nears Walgreens deal, Nabriva holds successful trials and two Equifax execs “retire”
  15. A biotech stock doubled after it got positive results on a drug to tackle the leading cause of infectious death in the US
  16. US STOCKS-Wall St hits new record highs as financials, industrials gain
  17. Stocks to Watch: Orbital ATK, Alphabet, Caterpillar, Equifax, Nabriva Therapeutics
  18. Markets head for new records
  19. Why Nabriva Shares Are Doubling
  20. UPDATE: Nabriva Therapeutics stock jumps 102% premarket on positive trial of pneumonia treatment

SEC Filings

  1. 8-K - Current report 171094271
  2. 424B5 - Prospectus [Rule 424(b)(5)] 171094207
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171091011
  4. 8-K - Current report 171089016
  5. 8-K - Current report 171088061
  6. 8-K - Current report 171064003
  7. 8-K - Current report 171043208
  8. DEF 14A - Other definitive proxy statements 171041309
  9. 8-K - Current report 171025057
  10. EFFECT - Notice of Effectiveness 171022840